Literature DB >> 6112241

Release of somatostatin-like immunoreactivity from the perfused canine thyroid. Selective stimulatory effect of calcium ions.

P Laurberg, H Orskov.   

Abstract

It is well accepted that the C cells of the thyroid contain somatostatin, but the role in local endocrine function has not yet been firmly established in this organ, and it has not been proved that thyroidal somatostatin is released into the circulation. We have measured the contents of somatostatin-like immunoreactivity in the effluent of canine thyroid glands perfused without recirculation with a synthetic buffer medium. During basal conditions a definite release was consistently found in the order of 10 pg/ml corresponding to 12 pg/min. The somatostatin-like immunoreactivity was studied in dilution experiments and by gel-filtration chromatography, and found to have properties identical to those of synthetic cyclic somatostatin, which was also recovered quantitatively when added to sampling tubes. Various compounds were infused in concentrations that are highly active in pancreas perfusion experiments. 14-min infusion of arginine, 5 and 11.5 mmol/liter; isoproterenol, 10 and 23.7 nmol/liter and 68.7 mumol/liter; acetylcholine, 5 mumol/liter, carbamylcholine, 10 and 100 mumol/liter; glucagon, 1 and 30 nmol/liter; and porcine calcitonin, 1 and 100 ng/ml did not affect the basal release of somatostatin-like immunoreactivity significantly. Neither did an increase from the control level of 4 mmol/liter glucose of 10 or 20 mmol/liter, nor an increase in the control level of 4.4 mmol/liter K+ to 7.5 or 14.4 mmol/liter. Each of these compounds were tested in three or four dogs. The effect of an increase in Ca++ from the control level of 1.5 mmol/liter to 2.25, 3.0, and 4.5 mmol/liter was tested in random order in five thyroid lobes. All three doses elicited an immediate increase in effluent somatostatin-like immunoreactivity. In most experiments the response was biphasic with an early spike, followed by a stable level that was maintained during prolonged Ca++ infusion. The secretory response was not diminished through a series of repeated short pulses of calcium infusion. The response to 3.0 mmol/liter Ca++ (control period 8.4 +/- 1.5, test period 337 +/- 110 pg/ml, mean +/- SE) and 4.5 mmol/liter Ca++ (control period 9.5 +/- 1.4, test period 386 +/- 125) were significantly higher than 2.25 mmol/liter Ca++ (control period 7.2 +/- 1.0 test period 140 +/- 39), while there was no significant difference between responses to the two high doses. Infusion of salmon calcitonin, 10 ng/ml and 1 microgram/ml; or porcine calcitonin, 1 microgram/ml during calcium stimulation (2.25 mmol/liter of Ca++) did not induce alterations in the release of somatostatin-like immunoreactivity. The results demonstrate that thyroidal somatostatin is mobilizable, and it appears to be selectively sensitive to calcium stimulation, indicating a possible role in calcitonin release control.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112241      PMCID: PMC370712          DOI: 10.1172/jci110174

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  A radioimmunoassay for growth hormone release-inhibiting hormone: method and quantitative tissue distribution.

Authors:  S Kronheim; M Berelowitz; B L Pimstone
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

2.  In vitro secretion of immunoreactive rat thyrocalcitonin.

Authors:  C W Cooper; W K Ramp; D I Becker; D A Ontjes
Journal:  Endocrinology       Date:  1977-07       Impact factor: 4.736

3.  Lack of effect of somatostatin on TSH induced T3 release and platelet function in normal man.

Authors:  J Faber; J Gormsen; T Friis; C Kirkegaard; U B Lauridsen; J Nerup; P Rogowski; K Siersbaek-Nielsen
Journal:  Horm Metab Res       Date:  1977-03       Impact factor: 2.936

4.  Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

Authors:  S R Bloom; C H Mortimer; M O Thorner; G M Besser; R Hall; A Gomez-Pan; V M Roy; R C Russell; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

5.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

6.  Central and peripheral localization of somatostatin. Immunoenzyme immunocytochemical studies.

Authors:  J A Parsons; S L Erlandsen; O D Hegre; R C McEvoy; R P Elde
Journal:  J Histochem Cytochem       Date:  1976-07       Impact factor: 2.479

7.  The relative contribution of thyroxine and triiodothyronine to the hormone secretion from the perfused canine thyroid during various degrees of stimulation.

Authors:  P Laurberg
Journal:  Endocrinology       Date:  1977-03       Impact factor: 4.736

8.  T4 and T3 release from the perfused canine thyroid isolated in situ.

Authors:  P Laurberg
Journal:  Acta Endocrinol (Copenh)       Date:  1976-09

9.  Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

Authors:  E Ipp; R E Dobbs; A Arimura; W Vale; V Harris; R H Unger
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

10.  [Influence of somatostatine on plasma level of calcitonin in the calf and the swine].

Authors:  J P Barlet; J M Garel
Journal:  C R Seances Soc Biol Fil       Date:  1975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.